AbbVie Inc. (LON:0QCV)

Market Cap	304.01B
Revenue (ttm)	44.37B
Net Income (ttm)	1.75B
Shares Out	n/a
EPS (ttm)	0.98
PE Ratio	174.04
Forward PE	16.64
Dividend	5.03 (2.21%)
Ex-Dividend Date	Oct 15, 2025

Volume	14,159
Average Volume	7,652
Open	228.25
Previous Close	227.25
Day's Range	225.58 - 228.64
52-Week Range	146.95 - 244.49
Beta	0.35
RSI	49.40
Earnings Date	Oct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QCV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD